Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer.

ABSTRACT: A major obstacle for the effective treatment of pancreatic ductal adenocarcinoma (PDAC) is its molecular heterogeneity, reflected by the diverse clinical outcomes and responses to therapies that occur. The tumors of patients with PDAC must therefore be closely examined and classified before treatment initiation in order to predict the natural evolution of the disease and the response to therapy. To stratify patients, it is absolutely necessary to identify biological markers that are highly specific and reproducible, and easily measurable by inexpensive sensitive techniques. Several promising strategies to find biomarkers are already available or under development, such as the use of liquid biopsies to detect circulating tumor cells, circulating free DNA, methylated DNA, circulating RNA, an

SUBMITTER: Iovanna J 

PROVIDER: S-EPMC7704461 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature